🧵6️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️

📌 #Zevaquenabant treatment effectively reduces #fibrosis in human precision-cut lung slices (#hPCLS).

📌 Pulmonary delivery of zevaquenabant may offer a more targeted and safer #therapeutic modality for #fibrotic #lung #diseases

🧵5️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️

📌Systems #pharmacology reveals that #zevaquenabant and #nintedanib treatments reverse distinct and shared #pulmonaryfibrosis related pathways, provides opportunity for future clinical trials to improve clinical efficacy.

🧵4️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️

📌 #Zevaquenabant attenuates multiple #fibrosis-related pathways in lungs

📌 Pulmonary delivery of zevaquenabant attenuated #fibrogenic #macrophages expressing Spp1, Trem2, Tgfb1, Mertk, Fabp5, Cd9, Cd63, Gpnmb, Fabp4

🧵3️⃣ ⚡️Therapeutic modality to improve safety ⚡️

📌🫁Pulmonary delivery of #zevaquenabant (#MRI1867) by lowering the systemic dose 20-fold retains superior therapeutic efficacy in mitigating PF by eliminating systemic exposure in animal model of #PulmonaryFibrosis